Fåhraeus Startup and Growth

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

Speqta is a performance marketing company that owns and operates an advertising network as well as several digital products and services.

Yazen is a digital healthcare provider focused on delivering personalized weight loss programs, primarily targeting middle-aged men dealing with obesity and potential testosterone deficiencies. The company connects users with a multidisciplinary team of professionals, including doctors, psychologists, dietitians, and personal trainers, to develop customized weight management plans. By leveraging data-driven insights, Yazen incorporates lifestyle changes and, when necessary, medical treatments to enhance both physical and mental well-being. The platform's holistic approach aims to empower individuals to achieve sustainable health improvements through expert guidance and support.

Airsonett is a medical device company focused on developing non-pharmaceutical treatments for allergic asthma and eczema. Its flagship product, the Air4, employs patented Temperature-controlled Laminar Airflow (TLA) technology to create a cleaner breathing environment. This non-invasive home device effectively reduces allergens and airborne irritants in the patient's vicinity during rest and sleep, providing significant relief for individuals suffering from allergic asthma and atopic eczema. Operating primarily in Sweden and the UK, Airsonett aims to enhance the quality of life for patients by offering effective prophylactic treatments that minimize reliance on traditional asthma medications.

Melius Pharma is a pharmaceutical company dedicated to the development of innovative treatments for interstitial lung diseases, with a particular emphasis on addressing severe conditions that exhibit significant unmet clinical needs. The company specializes in creating solutions for chronic cough associated with idiopathic pulmonary fibrosis, aiming to enhance the quality of care for patients suffering from these challenging respiratory conditions. By focusing on these targeted therapies, Melius Pharma seeks to improve health outcomes and provide healthcare professionals with effective treatment options for managing chronic cough.

Nygen Analytics specializes in providing cloud-based solutions for the analysis of single-cell genomic data. The company develops tools and services aimed at facilitating sustainable and cost-effective genomic data analysis. By focusing on user-centric applications, Nygen Analytics helps researchers overcome challenges in genomics research, streamlining processes and enhancing the accessibility of complex data. Their innovative platform is designed to support advancements in the field of genomics, making it easier for users to derive meaningful insights from their data.

Saveggy is a company that specializes in creating a bio-based edible coating for fruits and vegetables, offering a sustainable alternative to traditional plastic packaging. This innovative coating preserves the freshness and protective properties of produce while significantly reducing food waste along the supply chain. Saveggy's technology is fully scalable and uniquely complies with EU regulations for edible coatings, making it a pioneering solution in the food packaging sector. By focusing on environmentally friendly practices, Saveggy aims to ensure that more food reaches consumers, minimizing losses and promoting sustainability in the agricultural industry.

Moroxite F is a company that specializes in developing innovative treatments for fractures, particularly in patients with osteoporosis. Its primary focus is on a regenerative medicine that utilizes a prolonged release system for hydroxyapatite binding drugs, specifically designed to enhance the anchoring of implants in fragile bones. By delivering hydroxyapatite particles directly at the interface of bone, the company aims to improve implant fixation, thereby reducing the incidence of fixation failures and the need for re-operations. This approach not only seeks to enhance the quality of life for osteoporotic patients but also aims to lower societal costs associated with fracture management.

Brick is an app that solves the problem of electronics running out of battery. Download our app and find the nearest Brick station on the map, then rent a power bank (with cables) to charge your phone, tablet, headphones or whatever it is that is running out of battery. Return the power bank to any Brick station so that you can charge on the go. Stay in charge.

Oncorena AB is a pharmaceutical company based in Göteborg, Sweden, dedicated to developing innovative treatments for cancer, particularly advanced kidney cancer, also known as metastatic renal cancer. The company's primary focus is on the toxin orellanine, which is derived from specific mushroom species and has shown potential as a powerful anti-tumor agent. Oncorena aims to confirm the efficacy of orellanine in targeting and selectively destroying renal proximal tubular epithelial cells, including those that have transformed into cancerous cells and formed metastases. Through its research, Oncorena seeks to provide effective pharmacological solutions that can improve outcomes for patients battling this challenging form of cancer.